HIF1A and glioblastoma: Targeting the NF-κB-FAT1 axis might inhibit the important tumor-promoting pathway in glioblastoma because FAT1 and NF-κB independently enhance protumorigenic inflammation and upregulate the expression of HIF-1α/EMT/stemness in tumors [42].